<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>LVEF &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/lvef/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 27 Oct 2026 07:40:06 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>LVEF &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Mavacamten sharply lowers heart outflow obstruction in real-world Chinese patient cohort</title>
		<link>https://bioengineer.org/mavacamten-sharply-lowers-heart-outflow-obstruction-in-real-world-chinese-patient-cohort/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 07:40:06 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[beta blockers]]></category>
		<category><![CDATA[cardiac myosin inhibitor]]></category>
		<category><![CDATA[drug safety]]></category>
		<category><![CDATA[echocardiography]]></category>
		<category><![CDATA[high-sensitivity troponin I]]></category>
		<category><![CDATA[left ventricular outflow tract gradient]]></category>
		<category><![CDATA[LVEF]]></category>
		<category><![CDATA[mavacamten]]></category>
		<category><![CDATA[NT-proBNP]]></category>
		<category><![CDATA[obstructive hypertrophic cardiomyopathy]]></category>
		<category><![CDATA[Real-world evidence]]></category>
		<category><![CDATA[Retrospective study]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=460927</guid>

					<description><![CDATA[A 30-week real-world study of 222 Chinese patients found mavacamten reduced resting outflow tract gradients to 23.76 mmHg versus 78.49 mmHg on conventional therapy, with biomarker improvements but close monitoring for ejection fraction decline.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">460927</post-id>	</item>
	</channel>
</rss>
